GDF6, also known as BMP‐13, was the highest expressed ligand at 9% of patients with primary prostate cancer followed by BMP 2, 6, and 7 at 6% of patients, with all other ligands being expressed less than 5% of patients (Figure 1B). Here, GDF6 is linked to prostate carcinoma.